Join
Live feed
·
PRReleasevia Quantisnow
Entera Bio Ltd. logo

Entera Bio Receives Positive FDA Feedback on 12-Month Registrational Phase 3 Study for EB613 - the First Oral Anabolic Tablet in Development for Postmenopausal Women with Osteoporosis

ByQuantisnow·Wall Street's wire, on your screen.
ENTX· Entera Bio Ltd.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track ENTX (Entera Bio Ltd.) and more on Quantisnow.